Study of levetiracetam effect in neonatal seizure control

Study of levetiracetam effect in reduction of seizure frecuency in neonats with seizure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014070318334N1

Enrollment

Registered

2014-08-26

Start date

2014-05-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal seizure. ???? ??????

Interventions

Levetiracetam ?Tab 500mg per oral, 10mg/Kg , every 12 houres for 3 months.

Treatment - Drugs

Levetiracetam ?Tab 500mg per oral, 10mg/Kg , every 12 houres for 3 months

Eligibility

Sex/Gender

All

Age

1 Days to 29 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria: Gestational age = 35 weeks; Postnatal age = 29 days; Birth weight = 2000 grams; Parental consent obtained; Clinical seizures requiring treatment with an antiepileptic medication (as per the judgment of the clinician caring for the patient). Exclusion criteria: Infants with renal insufficiency indicated by serum creatinine > =2.0; Patients whose seizures were caused by electrolyte disturbances or hypoglycemia, or whose seizures did respond to pyridoxine .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Seizure frecuency. Timepoint: 4 weak. Method of measurement: According to mother daily note.	—

Secondary

Measure	Time frame
Seizure duration. Timepoint: 4weak. Method of measurement: According to mother daily note.;Side effect. Timepoint: 4weak. Method of measurement: According to lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Sedighi

Kermanshah University of Medical Sciences and Health Services

M.Sedighi@ kums.ac.ir+98 83 3721 8204

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026